Brucein D induces apoptosis in pancreatic adenocarcinoma cell line PANC-1 through the activation of p38-mitogen activated protein kinase

Cancer Letters

Volumn 281, Issue 1, 2009, Pages 42-52

  Lau, Sin Ting ^a,b   Lin, Zhi Xiu ^b   Liao, Yonghong ^c   Zhao, Ming ^b   Cheng, Christopher H K ^a   Leung, Po Sing ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c INSTITUTE OF MEDICINAL PLANT DEVELOPMENT   (China)

Author keywords

Apoptosis; Brucein D; p38 MAPK; PANC 1 cells; Signaling pathway

Indexed keywords

BRUCEINE D; CAMPTOTHECIN; CASPASE 3; CASPASE 8; CASPASE 9; DNA FRAGMENT; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BAK; PROTEIN BCL 2; ANTINEOPLASTIC AGENT; CASPASE; QUASSINOID DERIVATIVE; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DNA FRAGMENTATION; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ADENOCARCINOMA; CELL DIVISION; CYTOLOGY; DNA REPLICATION; DRUG ANTAGONISM; DRUG EFFECT; FIBROBLAST; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

BRUCEA JAVANICA;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CAMPTOTHECIN; CASPASES; CELL DIVISION; CELL LINE, TUMOR; DNA REPLICATION; ENZYME ACTIVATION; FIBROBLASTS; HUMANS; NEOPLASM PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PANCREATIC NEOPLASMS; QUASSINS;

EID: 67349190115     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.02.017     Document Type: Article

References (44)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., and Thun M.J. Cancer statistics, 2008. C.A. Cancer J. Clin. 58 (2008) 71-96
2. Lewis B.C. Development of the pancreas and pancreatic cancer. Endocrinol. Metab. Clin. North Am. 35 (2006) 397-404
3. Duffy J.P., Eibl G., Reber H.A., and Hines O.J. Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol. Cancer 2 (2003) 12
4. Barton-Burke M. Gemcitabine: a pharmacologic and clinical review. Cancer Nurs. 22 (1999) 176-183
5. Hui Y.F., and Reitz J. Gemcitabine: a cytidine analogue active against solid tumors. Am. J. Health Syst. Pharm. 54 (1997) 162-170
6. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarassoff P., Nelson R., Dorr F.A., Stephens C.D., and Von Hoff D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15 (1997) 2403-2413
7. Giroux V., Iovanna J., and Dagorn J.C. Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance. FASEB J. 20 (2006) 1982-1991
8. Shi X., Liu S., Kleeff J., Friess H., and Buchler M.W. Acquired resistance of pancreatic cancer cells towards 5-fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 62 (2002) 354-362
9. Storniolo A.M., Enas N.H., Brown C.A., Voi M., Rothenberg M.L., and Schilsky R. An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 85 (1999) 1261-1268
10. Lau S.T., Lin Z.X., Zhao M., and Leung P.S. Brucea javanica fruit induces cytotoxicity and apoptosis in pancreatic adenocarcinoma cell lines. Phytother. Res. 22 (2008) 477-486
11. Yang Z.Q., Xie H.Y., Wang J.Y., Sun T.M., and Li X. Chemical studies of the active antitumor components from the fruits of Brucea javanica (L.) Merr. Nat. Prod. Res. Develop. 8 (1996) 35-39
12. Skehan P., Storeng R., Scudiero D., Monks A., McMahan J., Vistica D., Warren J.T., Bokesch H., Kenny S., and Boyd M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82 (1990) 1107-1112
13. Lin Z.X., Hoult J.R., and Raman A. Sulphorhodamine B assay for measuring proliferation of a pigmented melanocyte cell line and its application to the evaluation of crude drugs used in the treatment of vitiligo. J. Ethnopharmacol. 66 (1999) 141-150
14. Pearson G., Robinson F., Beers Gibson T., Xu B.E., Karandikar M., Berman K., and Cobb M.H. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev. 22 (2001) 153-183
15. Saklatvala J., Rawlinson L., Waller R.J., Sarsfield S., Lee J.C., Morton L.F., Barnes M.J., and Farndale R.W. Role for p38 mitogen-activated protein kinase in platelet aggregation caused by collagen or a thromboxane analogue. J. Biol. Chem. 22 (1996) 6586-6589
16. Lau F.Y., Chui C.H., Gambari R., Kok S.H., Kan K.L., Cheng G.Y., Wong R.S., Teo I.T., Cheng C.H., Wan T.S., Chan A.S., and Tang J.C. Antiproliferative and apoptosis-inducing activity of Brucea javanica extract on human carcinoma cells. Int. J. Mol. Med. 16 (2005) 1157-1162
17. Matsumura Y. Polymeric micellar delivery systems in oncology. Jpn. J. Clin. Oncol. 38 (2008) 793-802
18. Fulda S., and Debatin K.M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25 (2006) 4798-4811
19. Galluzzi L., Zamzami N., De La Motte Rouge T., Lemaire C., Brenner C., and Kroemer G. Methods for the assessment of mitochondrial membrane permeabilization in apoptosis. Apoptosis 12 (2007) 803-813
20. Jin Z., and El-Deiry W.S. Overview of cell death signaling pathways. Cancer Biol. Ther. 4 (2005) 139-163
21. Ghobrial I.M., Witzig T.E., and Adjei A.A. Targeting apoptosis pathways in cancer therapy. C.A. Cancer J. Clin. 55 (2005) 178-194
22. Putcha G.V., Harris C.A., Moulder K.L., Easton R.M., Thompson C.B., and Johnson Jr. E.M. Intrinsic and extrinsic pathway signaling during neuronal apoptosis: lessons from the analysis of mutant mice. J. Cell Biol. 157 (2002) 441-453
23. Zapata J.M., Pawlowski K., Haas E., Ware C.F., Godzik A., and Reed J.C. A diverse family of proteins containing tumor necrosis factor receptor-associated factor domains. J. Biol. Chem. 276 (2001) 24242-24252
24. Saelens X., Festjens N., Vande Walle L., van Gurp M., van Loo G., and Vandenabeele P. Toxic proteins released from mitochondria in cell death. Oncogene 23 (2004) 2861-2874
25. Wajant H. The Fas signaling pathway: more than a paradigm. Science 296 (2002) 1635-1636
26. Jaattela M. Escaping cell death: survival proteins in cancer. Exp. Cell Res. 248 (1999) 30-43
27. Puthalakath H., Huang D.C., O'Reilly L.A., King S.M., and Strasser A. The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol. Cell 3 (1999) 287-296
28. Letai A., Bassik M.C., Walensky L.D., Sorcinelli M.D., Weiler S., and Korsmeyer S.J. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2 (2002) 183-192
29. Wei M.C., Lindsten T., Mootha V.K., Weiler S., Gross A., Ashiya M., Thompson C.B., and Korsmeyer S.J. tBID a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev. 14 (2000) 2060-2071
30. Boldt S., Weidle U.H., and Kolch W. The role of MAPK pathways in the action of chemotherapeutic drugs. Carcinogenesis 23 (2002) 1831-1838
31. Olson J.M., and Hallahan A.R. P38 MAP kinase: a convergence point in cancer therapy. Trends Mol. Med. 10 (2004) 125-129
32. Park S.J., and Kim I.S. The role of p38 MAPK activation in auranofin-induced apoptosis of human promyelocytic leukaemia HL-60 cells. Br. J. Pharmacol. 146 (2005) 506-513
33. Wada T., Stepniak E., Hui L., Leibbrandt A., Katada T., Nishina H., Wagner E.F., and Penninger J.M. Antagonistic control of cell fates by JNK and p38-MAPK signaling. Cell Death Differ. 15 (2008) 89-93
34. Edlund S., Bu S., Schuster N., Aspenström P., Heuchel R., Heldin N.E., ten Dijke P., Heldin C.H., and Landstrom M. Transforming growth factor-beta1 (TGF-beta)-induced apoptosis of prostate cancer cells involves Smad7-dependent activation of p38 by TGF-beta-activated kinase 1 and mitogen-activated protein kinase kinase 3. Mol. Biol. Cell 14 (2003) 529-544
35. Cobb M.H., and Goldsmith E.J. How MAP kinases are regulated. J. Biol. Chem. 270 (1999) 14843-14846
36. Makin G., and Dive C. Modulating sensitivity to drug-induced apoptosis: the future for chemotherapy. Breast Cancer Res. 3 (2001) 150-153
37. Ono K., and Han J. The p-38 signal transduction pathway: activation and function. Cell. Signal. 12 (2000) 1-13
38. Deacon K., Mistry P., Chernoff J., Blank J.L., and Patel R. P38 Mitogen-activated protein kinase mediates cell death and p21-activated kinase mediates cell survival during chemotherapeutic drug-induced mitotic arrest. Mol. Biol. Cell 14 (2003) 2071-2087
39. Holmes W.F., Soprano D.R., and Soprano K.J. Early events in the induction of apoptosis in ovarian carcinoma cells by CD437: activation of the p38 MAP kinase signal pathway. Oncogene 22 (2003) 6377-6386
40. Losa J.H., Parada Cobo C., Viniegra J.G., Sánchez-Arevalo Lobo V.J., Ramóny Cajal S., and Sánchez-Prieto R. Role of the p38 MAPK pathway in cisplatin-based therapy. Oncogene 22 (2003) 3998-4006
41. Frey R.S., and Singletary K.W. Genistein activates p38 mitogen-activated protein kinase, inactivates ERK1/ERK2 and decreases Cdc25C expression in immortalized human mammary epithelial cells. J. Nutr. 133 (2003) 226-231
42. Lavelle D., DeSimone J., Hankewych M., Kousnetzova T., and Chen Y.H. Decitabine induces cell cycle arrest at the G1 phase via p21(WAF1) and the G2/M phase via the p38 MAP kinase pathway. Leuk. Res. 27 (2003) 999-1007
43. Wang X., McGowan C.H., Zhao M., He L., Downey J.S., Fearns C., Wang Y., Huang S., and Han J. Involvement of the MKK6-p38gamma cascade in gamma-radiation-induced cell cycle arrest. Mol. Cell Biol. 20 (2000) 4543-4552
44. Zhang Z., Leonard S.S., Huang C., Vallyathan V., Castranova V., and Shi X. Role of reactive oxygen species and MAPKs in vanadate-induced G(2)/M phase arrest. Free Rad. Biol. Med. 34 (2003) 1333-1342